Fast Five Quiz: COVID-19 Vaccines

Glenn Wortmann, MD


October 15, 2021

Cases of myocarditis and pericarditis in adolescents and young adults were reported starting in the spring of 2021 after mRNA vaccination, although no causal relationship has been established between vaccination and these adverse events. Reported cases have occurred predominantly in boys and young men aged 16 years and older. The typical onset has been within several days after mRNA COVID-19 vaccination, more often after the second than the first dose. Symptoms and diagnostic findings have included chest pain, elevated cardiac enzymes, and ST- or T-wave changes. Available outcome data indicate that patients generally recover from symptoms of myocarditis or pericarditis. There is still uncertainty about the true rates of myocarditis after mRNA vaccines, but a benefit-risk assessment from the Centers for Disease Control and Prevention concluded in favor of vaccination for all age and sex groups.

Guillain-Barré syndrome is an adverse event that has been reported in people who have received a viral vector vaccine. The cases have largely been reported about 2 weeks after vaccination, mostly in men aged 50 years and older. Rare cases of thrombosis and thrombocytopenia syndrome have also been reported after viral vector vaccination. Women younger than 50 years of age are at increased risk for this rare event. Reports of death after COVID-19 vaccination are also rare, and a causal link has not been established to the vaccines.

Learn more about COVID-19 vaccine safety.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.